Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 4:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1057–1080 of 8,440 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Metabolism Disorder, Glucose Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of the Fixed Dose Combination of 5 mg Saxagliptin and 500 mg Metformin XR Tablet (Manufactured in Mt Vernon, IN) Relative to 5 mg Saxagliptin Tablet and 500 mg Metformin XR Tablet (Manufactured in Evansville, IN)

NCT01192139
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
saxagliptin, metformin XR, saxagliptin + metformin XR (FDC tablet)
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 45 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2015 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Targeting the Carotid Bodies to Reduce Disease Risk Along the Diabetes Continuum

NCT05219994
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Hyperoxia Exposure, Normoxia Exposure
Other
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 65 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 19, 2026, 4:53 PM EDT
Withdrawn Phase 3 Interventional

A Study to Evaluate ITCA 650 Compared to Glimepiride as Add on Therapy for the Treatment of Type 2 Diabetes

NCT01455922
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
ITCA 650, glimepiride
Drug
Lead sponsor
Intarcia Therapeutics
Industry
Eligibility
18 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Hayward, California
Source: ClinicalTrials.gov public record
Updated Dec 25, 2012 · Synced Oct 19, 2026, 4:53 PM EDT
Completed No phase listed Observational

Potential Eligibility and Estimated Preventable Cardiovascular Disease Events From Inclisiran Treatment in the United States

NCT07214857
View directory record Official record
Conditions
Cardiovascular Disease
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
1,385 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 19, 2026, 4:53 PM EDT
Active, not recruiting Not applicable Interventional

Can Gut Bacteria Predict Who Benefits Most From Exercise? A Gut Supplement to Help Exercise Non-Responders

NCT07180446
View directory record Official record
Conditions
Obesity &Amp; Overweight
Interventions
Cardiovascular Exercise, Butyrate
Behavioral · Dietary Supplement
Lead sponsor
Texas Christian University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Effect of Metformin on Insulin Sensitivity and Pan-Arterial Vascular Function in Adults With Metabolic Syndrome

NCT02633488
View directory record Official record
Conditions
Metabolic Syndrome, Insulin Sensitivity
Interventions
Placebos, metformin
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 60 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 23, 2020 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

User Performance Evaluation of an Investigational Blood Glucose Monitoring System

NCT01410773
View directory record Official record
Conditions
Diabetes
Interventions
Ninja 2 Investigational Blood Glucose Monitoring System
Device
Lead sponsor
Ascensia Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
1
States / cities
Mishawaka, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 29, 2016 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Study of Sildenafil Citrate on Insulin Resistance in African American

NCT01334554
View directory record Official record
Conditions
Metabolic Syndrome, Obesity
Interventions
Sildenafil, Placebo
Drug
Lead sponsor
Vanderbilt University Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Mar 27, 2017 · Synced Oct 19, 2026, 4:53 PM EDT
Recruiting Not applicable Interventional

Glucose and Activity Tracking for Sedentary Behavior Interventions in Older People With Type 2 Diabetes (TRACK T2D)

NCT07524205
View directory record Official record
Conditions
Diabetes Mellitus, Type 2
Interventions
SB Intervention
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
55 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Recruiting Phase 4 Interventional

Effect of Zinc on Glucose Homeostasis

NCT05835037
View directory record Official record
Conditions
Prediabetic State, Hyperglycemia
Interventions
Zinc Gluconate 30 MG, Placebo
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
Lancaster, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Acute Effect of Mango Intake (Mangifera Indica L.) on Blood Pressure and Blood Glucose

NCT04057495
View directory record Official record
Conditions
Blood Pressure
Interventions
further fasting, white bread consumption, mango consumption
Other
Lead sponsor
University of California, Davis
Other
Eligibility
50 Years to 70 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Jul 23, 2021 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 4 Interventional Results available

GLP-1 Therapy: The Role of IL-6 Signaling and Adipose Tissue Remodeling in Metabolic Response

NCT04387201
View directory record Official record
Conditions
Glucose Intolerance, Overweight and Obesity, Drug Effect, Adiposity
Interventions
Cyanocobalamin, Dulaglutide
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years to 50 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 5, 2024 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 2 Interventional Results available

Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Multiple Oral Bedtime Doses of ORMD-0801 in Adult Patients With Type 2 Diabetes Mellitus (T2DM)

NCT01889667
View directory record Official record
Conditions
Diabetes Mellitus Type 2
Interventions
ORMD-0801 Dose # 1, ORMD-0801 Dose # 2, Placebo
Drug
Lead sponsor
Oramed, Ltd.
Industry
Eligibility
20 Years to 70 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Tustin, California
Source: ClinicalTrials.gov public record
Updated Apr 16, 2015 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 1 Interventional

Early Phase Pre-Clinical and Initial Clinical Research on Epicatechin (Part 2)

NCT02656212
View directory record Official record
Conditions
Pre-diabetes
Interventions
epicatechin, Placebo
Drug
Lead sponsor
Veterans Medical Research Foundation
Other
Eligibility
21 Years to 75 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Apr 28, 2016 · Synced Oct 19, 2026, 4:53 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Insulin Balanced Infusion System

NCT01291719
View directory record Official record
Conditions
Hyperglycemia, Diabetes
Interventions
glucose and insulin infusions
Device
Lead sponsor
Admetsys Corporation
Industry
Eligibility
21 Years to 85 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2026
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jul 30, 2024 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Results available

Diabetes Closed-Loop Project 6 (DCLP6): Fully Automated Closed-Loop Control in Type 1 Diabetes Using Meal Anticipation

NCT04877730
View directory record Official record
Conditions
Type 1 Diabetes
Interventions
Fully Closed Loop (FCL), Fully Closed Loop with meal anticipation module (FCL+), Hybrid Closed Loop (HCL)
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 23, 2024 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Phase 4 Interventional

Effect of Immediate Hemoglobin A1c on Glycemic Control in Children With Type I Diabetes Mellitus

NCT00898534
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Glycemic Control
Interventions
Bayer DCA2000+ Hemoglobin A1c analyzer
Device
Lead sponsor
Boston Children's Hospital
Other
Eligibility
2 Years to 18 Years
Enrollment
234 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 12, 2009 · Synced Oct 19, 2026, 4:53 PM EDT
Suspended Not applicable Interventional Accepts healthy volunteers

Protein, Amino Acids & Insulin & Glucagon Secretion in Humans

NCT01471509
View directory record Official record
Conditions
Type 2 Diabetes, Metabolic Syndrome
Interventions
water, glucose with or without amino acid
Other
Lead sponsor
Minneapolis Veterans Affairs Medical Center
Federal
Eligibility
18 Years to 80 Years
Enrollment
300 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1982 – 2017
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Oct 19, 2026, 4:53 PM EDT
Terminated Phase 2 Interventional

Study of FibroGen (FG)-3019 in Subjects With Type 2 Diabetes Mellitus and Kidney Disease on ACEi and/or ARB Therapy

NCT00913393
View directory record Official record
Conditions
Type 2 Diabetes Mellitus, Diabetic Nephropathy, Diabetic Kidney Disease
Interventions
FG-3019, Placebo
Drug
Lead sponsor
Kyntra Bio
Industry
Eligibility
18 Years to 75 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
28
States / cities
Tempe, Arizona • Buena Park, California • Lakewood, California + 25 more
Source: ClinicalTrials.gov public record
Updated Feb 22, 2019 · Synced Oct 19, 2026, 4:53 PM EDT
Terminated Phase 4 Interventional Results available

Assessment of Dapagliflozin on Vascular Health in Patients With Type 2 Diabetes

NCT05139914
View directory record Official record
Conditions
Diabetes Mellitus, Type 2, Endothelial Dysfunction
Interventions
Dapagliflozin, Placebo
Drug · Other
Lead sponsor
Boston University
Other
Eligibility
30 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 11, 2026 · Synced Oct 19, 2026, 4:53 PM EDT
Completed No phase listed Observational

Knee Steroid Injection and Blood Sugar Signatur

NCT04317404
View directory record Official record
Conditions
Diabetes, Knee Osteoarthritis
Interventions
40 mg Triamcinolone acetonide
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
11 participants
Timeline
2020 – 2022
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jan 18, 2023 · Synced Oct 19, 2026, 4:53 PM EDT
Completed No phase listed Observational

FreeStyle Libre Flash Glucose Monitoring System Accuracy Study

NCT03141892
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
FreeStyle Libre Flash Glucose Monitoring System
Device
Lead sponsor
Abbott Diabetes Care
Industry
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
4
States / cities
Santa Barbara, California • Walnut Creek, California • Idaho Falls, Idaho + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 11, 2017 · Synced Oct 19, 2026, 4:53 PM EDT
Terminated Phase 2 Interventional

The Application of Extremely Low Level Magnetic Fields as Adjunctive Treatment for Type II Diabetes

NCT00982293
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Resonator device, Resonator device - sham
Device
Lead sponsor
pico-tesla Magnetic Therapies, LLC
Industry
Eligibility
21 Years to 80 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
1
States / cities
Littleton, Colorado
Source: ClinicalTrials.gov public record
Updated May 5, 2011 · Synced Oct 19, 2026, 4:53 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

CALERIE: Comprehensive Assessment of Long-Term Effects of Reducing Intake of Energy

NCT00427193
View directory record Official record
Conditions
Aging
Interventions
Caloric Restriction (CR), Control
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years to 50 Years
Enrollment
238 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2012
U.S. locations
3
States / cities
Baton Rouge, Louisiana • Boston, Massachusetts • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Mar 16, 2022 · Synced Oct 19, 2026, 4:53 PM EDT